The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The 2022 Tandem Meetings | Challenges of in vivo gene editing for diseases of the hematopoietic system
Agnieszka Czechowicz, MD, PhD, Stanford University, Stanford, CA, outlines the obstacles to in vivo gene editing for diseases of the hematopoietic system, which mainly include concerns about the toxicity of this procedure. Currently, patients are treated with ex vivo gene editing and allogeneic cell therapies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
